NASDAQ:BDSI - BioDelivery Sciences International Stock Price, Forecast & News

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) posted its quarterly earnings results on Tuesday, November, 12th. The specialty pharmaceutical company reported $0.33 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.01) by $0.34. The specialty pharmaceutical company had revenue of $30.31 million for the quarter, compared to analysts' expectations of $28.86 million. View BioDelivery Sciences International's Earnings History.

BioDelivery Sciences International is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for BioDelivery Sciences International.

BioDelivery Sciences International updated its FY 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $110-110 million, compared to the consensus revenue estimate of $111 million.

7 Wall Street analysts have issued 12-month price objectives for BioDelivery Sciences International's shares. Their forecasts range from $6.00 to $9.00. On average, they anticipate BioDelivery Sciences International's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 51.8% from the stock's current price. View Analyst Price Targets for BioDelivery Sciences International.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioDelivery Sciences International in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioDelivery Sciences International.

News headlines about BDSI stock have trended extremely negative on Sunday, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. BioDelivery Sciences International earned a daily sentiment score of -5.0 on InfoTrie's scale. They also assigned news coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for BioDelivery Sciences International.

BioDelivery Sciences International saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 3,060,000 shares, an increase of 39.7% from the January 15th total of 2,190,000 shares. Based on an average trading volume of 1,530,000 shares, the days-to-cover ratio is presently 2.0 days. Approximately 3.7% of the company's stock are short sold. View BioDelivery Sciences International's Current Options Chain.

Some companies that are related to BioDelivery Sciences International include AbbVie (ABBV), The Medicines (MDCO), Assembly Biosciences (ASMB), Ampio Pharmaceuticals (AMPE), Melinta Therapeutics (MLNT), Acura Pharmaceuticals (ACUR), Akorn (AKRX), Allergan (AGN), Bristol-Myers Squibb (BMY), Corcept Therapeutics (CORT), Cumberland Pharmaceuticals (CPIX), Eli Lilly And Co (LLY), Endo International (ENDP), Horizon Therapeutics (HZNP) and Jazz Pharmaceuticals (JAZZ).

Based on aggregate information from My MarketBeat watchlists, some companies that other BioDelivery Sciences International investors own include TG Therapeutics (TGTX), Eldorado Gold (EGO), Synergy Pharmaceuticals (SGYP), NVIDIA (NVDA), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), Horizon Therapeutics (HZNP), Progenics Pharmaceuticals (PGNX), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).

BioDelivery Sciences International's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Emerald Mutual Fund Advisers Trust (2.23%), State Street Corp (2.09%), Renaissance Technologies LLC (1.24%), Goldman Sachs Group Inc. (1.05%), Blair William & Co. IL (1.03%) and 1492 Capital Management LLC (0.92%). Company insiders that own BioDelivery Sciences International stock include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Mark A Sirgo, Mary Theresa Coelho, Paolantonio Ernest Robert De, Scott M Plesha and Thomas B Smith. View Institutional Ownership Trends for BioDelivery Sciences International.

BDSI stock was sold by a variety of institutional investors in the last quarter, including Penn Capital Management Co. Inc., J. Goldman & Co LP, Mackay Shields LLC, Los Angeles Capital Management & Equity Research Inc., Oxford Asset Management LLP, PNC Financial Services Group Inc., New York State Common Retirement Fund and California Public Employees Retirement System. Company insiders that have sold BioDelivery Sciences International company stock in the last year include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Mark A Sirgo, Mary Theresa Coelho, Scott M Plesha and Thomas B Smith. View Insider Buying and Selling for BioDelivery Sciences International.

BDSI stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Marshall Wace LLP, EAM Investors LLC, Goldman Sachs Group Inc., Panagora Asset Management Inc., Assenagon Asset Management S.A., State Street Corp and EAM Global Investors LLC. View Insider Buying and Selling for BioDelivery Sciences International.

Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BDSI stock can currently be purchased for approximately $5.27.